Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
220 CHF | -0.05% | -2.70% | -10.02% |
Apr. 18 | Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment | DJ |
Apr. 18 | ROCHE HOLDINGS AG : UBS sticks Neutral | ZD |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- With an enterprise value anticipated at 3.16 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.02% | 194B | A+ | ||
+27.97% | 676B | C+ | ||
+23.58% | 554B | B | ||
-7.02% | 349B | C+ | ||
+14.85% | 318B | B- | ||
+6.25% | 291B | C+ | ||
+2.96% | 210B | B+ | ||
-0.41% | 204B | B- | ||
-11.81% | 144B | C+ | ||
-8.80% | 142B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROG Stock
- Ratings Roche Holding AG